Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Osteoporosis medical treatments

Note that osteoporosis is a worldwide problem that increases due to the aging of all populations. It is important to diagnose osteoporosis early in order to prevent its progression and lessen the economic consequences for the society. Osteoporosis can be caused or worsened by medications and this should be avoided. Pain from fractures and deformation of the spine often has grave consequences for the individual and can be avoided by a combination of lifestyle changes and appropriate medical treatment. [Pg.69]

Furthermore, Pharma companies have not yet been very successful in treating the symptoms or in slowing the progression of many major diseases such as Alzheimer disease or osteoporosis. That being said, the slowing of disease progression can hardly be called an actual improvement, and it should not be the final goal of medical treatment. Best would... [Pg.13]

The two FDA-approved indications for osteoporosis medications— prevention and treatment—were created before enhanced understanding of the disease. The prevention of osteoporosis indication applies to drugs that demonstrate maintenance of BMD above the osteoporosis threshold (T-score >-2.5) compared to placebo over a 3-year period in patients with low bone mass (T-score <-1.0). Although commonly misinterpreted by clinicians, this indication does not infer a fracture risk reduction, the primary therapeutic end point. The treatment indication, however, is based on a drug s ability to demonstrate fracture risk reduction, either at the vertebral or nonvertebral sites, compared to placebo. [Pg.1655]

Calcitonin is released from the thyroid gland when serum calcium is elevated. Salmon calcitonin is used clinically because it is more potent and longer lasting than the mammalian form. Pharmacologic doses decrease bone resorption. Calcitonin is indicated for osteoporosis treatment for women at least 5 years past menopause. Although the agent is also used in men, it is not approved for this indication. Because calcitonin reduces fracture risk to a lesser extent than other osteoporosis medications, calcitonin is reserved for second-line treatment. [Pg.1659]

Teriparatide contains the first 34 amino acids in human parathyroid hormone and represents a novel approach to osteoporosis treatment. Although hyperparathyroidism leads to bone loss (see Fig. 88-3), therapeutic doses (for shorter periods of time) conversely improve BMD and rednce fractnre risk. Parathyroid hormone is currently the only approved osteoporosis medication that works by stimulating bone formation. Becanse of adverse effects and cost concerns, teriparatide is reserved for treating those at high risk of osteoporosis-related fracture who cannot or will not take or have failed bisphosphonate therapy. [Pg.1660]

Antacids are used in die treatment of hyperacidity, such as heartburn, gastroesoph eal reflux, sour stomach, acid indigestion, and in the medical treatment of peptic ulcer. Many antacid preparations contain more than one ingredient. An additional use for aluminum carbonate is in die treatment of hyiDeqihosphatemia or for use widi a low phosphate diet to prevent formation of phosphate urinaiy ston. Clalcium carbonate may be used in treating calcium deficiency states such as menopausal osteoporosis. M nesium oxide may be used in the treatment of m nesium deficiencies or m nesium depletion from malnutrition, restricted diet, or alcoholism. [Pg.466]

Estrogen currently is indicated for the treatment of moderate to severe vasomotor symptoms and vulvovaginal atrophy associated with menopause. In addition, it is indicated for the prevention of postmenopausal osteoporosis in women with significant risk however, it is recommended that non-estrogen medications receive consideration for long-term use. Oral or transdermal estrogen products should be prescribed at the lowest... [Pg.768]

AACE Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis ... [Pg.866]

Primary osteoporosis is the most common form of the condition. The secondary form of osteoporosis is diagnosed when an illness and/or medications are present with a negative impact on BMD. Examples of common chronic conditions in old people that can cause secondary osteoporosis are seen in Box 5.14. Examples of drugs that can cause secondary osteoporosis are glucocorticoids, too high doses of thyroid hormone, anticonvulsants, and heparin. Especially the use of glucocorticoids has been known to cause severe osteoporosis even within a short period of treatment. Depending on the doses the development of osteoporosis can occur within a few weeks or months. [Pg.68]

TransPharma-Medical, an Israeli-based pharmaceutical company, is investigating the transdermal delivery of human parathyroid hormone fragment for the treatment of osteoporosis in addition to the delivery of human growth hormone [41], This technology utilizes a 1-cm2 patch that creates small channels or holes in the stratum... [Pg.804]

Lifestyle changes are frequently an aspect of treatment. Medications to treat osteoporosis,... [Pg.190]

Olanzapine, already mentioned in CHEC-II(1996), has become one of the most commonly used atypical anti-psychotics. Strontium ranelate <2005MI728> has emerged as a novel medication in the treatment of osteoporosis. It increases the synthesis of collagen and noncollagenic proteins in vivo. [Pg.934]

Before starting HRT patients should be assessed individually considering their risk of osteoporosis, the current status of their liver disease, and any other coexisting medical risks. They should also be assessed for any history, including family history, of jaundice. The risks and potential benefits of treatment should be carefully explained. [Pg.260]

Hypertension. Nearly half of those with hypertension receive no treatment. Yet it is the chief cause of stroke in people under the age of 65. Direct medical expenses in 2000 exceeded 25 billion. Lost wages and decreased produchvity contributed to another 8 billion. Osteoporosis. Most sufferers receive no or little treatment. Ninety percent of women and 99% of men receive no treatment. Hypercholesterolemia. Over 1.5 millions will die from myocardial inf-archon (Ml) and many survivors will have serious morbidity issues. The prevention of coronary heart disease through lipid-lowering and... [Pg.497]

Orthopedists are trained in treating several degenerative diseases such as arthritis, osteoporosis, carpal tunnel syndrome, and so on. The treatment options may vary from making diet changes, medications, steroid injections, and incorporating exercise in the daily routine to surgical procedures and hormone replacement therapy. [Pg.688]

Treatment of secondary osteoporosis varies depending on the actual disease process which has produced the osteoporosis, and may include adjustments to thyroid medication, dietary supplementation with calcium or vitamin D (which is involved in the ability of the intestine to absorb calcium in the diet), or other treatment of the primary disease. [Pg.698]

Treatment of actual symptoms of osteoporosis include pain medications and heat for vertebral compressions, simple casts for uncomplicated fractures, or hip replacement surgery for more complicated hip fractures. [Pg.698]

Both undertreatment and underutilization of medications are common problems in the elderly. It is often a result of stereotyping by healthcare professionals, lack of education of managing medications in the elderly, and lack of research. Examples include treatment of hypertension, prescribing hormone therapy, osteoporosis, treating MI, lipid management, pain management, and depression. [Pg.1922]

One of the ideal situations in the treatment of disease is the delivery of efficacious medication to the site of action in a controlled and continual manner at the appropriate concentration. Controlled-released, biodegradable nanoparticles that can be loaded with the appropriate drug products have been developed to treat conditions such as cancer, arthritis, and osteoporosis. In view of their low toxicity and their protein-binding properties, the nanoparticles may be useful in the oral administration of peptides, proteins, and oligonucleotides, especially for vaccination. [Pg.313]

No single, widely accepted treatment guideline exists for osteoporosis. Several organizations have suggested various treatment approaches, most of which are based more on consensus opinion than evidence-based medical data. [Pg.1655]

Alendronate sodium (10 mg/day) is indicated for the treatment of osteoporosis in postmenopausal women and of Paget s disease. It acts as a specihc inhibitor of osteoclast-mediated bone resorption. The osteoclasts adhere normally to the bone surface but lack the ruffled border that is indicative of active resorption. Alendronate does not interfere with osteoclast recruitment or attachment, but it does inhibit osteoclast activity. Bones examined 6 and 49 days after ( H)alendronate administration showed that normal bone was formed on top of the alendronate, which was incorporated in bone matrix. Alendronate is not pharmacologically active thus, it must be continuously administered to suppress osteoclasts on newly formed resorption surfaces. Calcium supplements, antacids, and other oral medications will interfere with absorption of Fosamax. Therefore, patients must wait at least one hour before taking Fosamax. [Pg.54]


See other pages where Osteoporosis medical treatments is mentioned: [Pg.466]    [Pg.1322]    [Pg.49]    [Pg.1663]    [Pg.503]    [Pg.1143]    [Pg.292]    [Pg.856]    [Pg.69]    [Pg.336]    [Pg.962]    [Pg.1033]    [Pg.208]    [Pg.1143]    [Pg.4]    [Pg.14]    [Pg.375]    [Pg.707]    [Pg.357]    [Pg.520]    [Pg.224]    [Pg.872]    [Pg.3179]    [Pg.109]    [Pg.1503]    [Pg.164]    [Pg.266]   
See also in sourсe #XX -- [ Pg.298 ]




SEARCH



Osteoporosis

Osteoporosis treatment

© 2024 chempedia.info